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Abstract	1	 	 Dendritic	cells	(DCs)	are	critical	antigen	presenting	cells	that	link	the	innate	and	2	 adaptive	immune	systems.	DCs	are	activated	through	a	variety	of	receptors	and	respond	3	 with	a	diverse	array	of	metabolic	changes	that	are	not	yet	well	understood.	IL-1β	is	a	key	4	 inflammatory	cytokine	produced	by	DCs	when	they	are	activated	through	both	toll-like	5	 receptors	and	C-type	lectin	receptors.	IL-1β	is	activated	by	the	inflammasome	signaling	6	 complex	but	how	the	inflammasome	is	controlled	by	glycolysis	is	not	yet	well	understood.	7	 We	demonstrate	that	DC	activation	through	TLR	or	C-type	lectin	receptors	induces	a	shift	8	 to	aerobic	glycolytic	metabolism.	We	show	that	while	the	transcription	of	IL-1β	in	DCs	9	 activated	through	both	these	receptors	is	not	under	glycolytic	control,	whether	or	not	10	 translation	of	IL-1β	is	under	glycolytic	control	remains	unclear.	These	findings	provide	new	11	 information	on	Dectin-1	mediated	metabolic	reprogramming	in	DCs.	Understanding	the	12	 link	between	metabolic	changes	and	Dectin-1-mediated	DC	activation	has	broad	13	 implications	for	improved	vaccine	design	and	clinical	intervention	to	fungal	infection.		14	 	15	
Introduction	16	
Overview	of	Dendritic	Cells		17	 Dendritic	cells	(DCs),	a	type	of	innate	immune	cell,	are	specialized	for	patrolling	18	 tissue	for	pathogens	and	presenting	peptides	from	these	pathogens	to	other	immune	cells	19	 in	order	to	activate	inflammatory	responses.	Functionally,	DCs	are	the	link	between	the	20	 innate	and	adaptive	immune	systems	(Hoebe,	Janssen,	&	Beutler,	2004).	Innate	immunity	21	 refers	to	the	cells	including	DCs,	macrophages,	and	neutrophils	that	can	recognize	22	
			 3	pathogen	associated	molecular	patterns	(PAMPs)	and	clear	infections	or	activate	the	23	 adaptive	immune	system.	The	adaptive	immune	system	is	the	other	integral	part	of	the	24	 immune	system	and	consists	of	B	and	T	cells	that	are	activated	by	DCs	and	other	antigen	25	 presenting	cells,	and	is	characterized	by	immunological	memory	to	specific	antigens	26	 (Hoebe	et	al.,	2004).		27	 	28	
The	Importance	of	Dendritic	Cells	29	 DCs	are	prominent	antigen	presenting	cells	(APCs)	that	are	critical	in	the	activation	30	 of	T	cells,	which	in	turn	activate	a	coordinated	immune	response.	APCs	display	peptides	31	 non-selectively	on	cell	surface	molecules	that	are	recognized	by	T	cells.	If	the	T	cell	32	 recognizes	a	presented	peptide,	it	will	become	activated.	Unlike	B	cells,	T	cells	cannot	33	 recognize	unprocessed	antigens.	Instead,	T	cells	recognize	antigens	presented	on	a	major	34	 histocompatibility	complex	(MHC)	class	I	and	II	molecules	on	the	surface	of	APCs.	DCs	are	35	 present	in	the	peripheral	tissues,	the	spleen,	and	lymph	nodes	in	an	immature	state.	They	36	 do	not	actively	proliferate	except	in	small	bursts,	and	instead	are	replaced	by	37	 hematopoietic	cells	from	the	blood	and	bone	marrow	(Merad,	Sathe,	Helft,	Miller,	&	Mortha,	38	 2013).	DC	activation	of	T	cells	occurs	in	two	steps.	First,	the	T	cell	must	recognize	the	39	 specific	peptide	or	molecule	bound	to	MHC	on	the	DC	surface.	Second,	costimulatory	40	 molecules,	such	as	CD40	and	CD86,	produced	by	the	DC	must	bind	receptors	on	the	T	cell,	41	 leading	to	activation	of	the	T	cell.	Often	times,	MHC	expression	on	tumor	and	infected	cells	42	 is	lower	than	normal,	decreasing	the	chances	that	an	antigen-specific	T	cell	clone	will	43	 encounter	the	peptide	complex	on	its	own	and	become	activated.	Chances	of	activation	are	44	 also	decreased	because	co-stimulatory	molecules	that	help	activate	T	cells	are	also	45	
			 4	downregulated	in	infected	cells.	DCs	circumvent	this	problem	by	expressing	large	amounts	46	 of	MHC-peptide	complexes	and	co-stimulatory	molecules	that	help	activate	T	cells	and	47	 therefore	an	immune	response.	In	addition,	DCs	secrete	soluble	inflammatory	mediators	48	 called	cytokines,	which	are	inflammatory	molecules	that	signal	to	the	rest	of	the	immune	49	 system	when	there	is	a	pathogen	in	the	body.	DC	migration	to	lymph	nodes	upon	50	 recognition	of	antigens	allows	pathogens	which	entered	almost	anywhere	in	the	body	to	be	51	 presented	to	the	T-cells,	leading	to	systemic	activation	of	the	inflammatory	response	52	 (Banchereau	&	Steinman,	1998).		53	 DCs	play	a	critical	role	in	promoting	immune	tolerance,	a	state	of	suppressing	self-54	 reactive	immune	responses.	Autoreactive	T	cells	are	constantly	generated	due	to	the	55	 random	rearrangement	of	genes	to	create	new	T	cell	receptors.	These	autoreactive	T	cells	56	 are	normally	clonally	deleted	during	negative	selection	in	the	thymus	before	they	can	reach	57	 systemic	circulation.	Although	thymic	epithelial	cells	express	some	tissue-specific	antigens,	58	 other	mechanisms	exist	to	ensure	a	more	comprehensive	exposure	to	self-antigens	as	well	59	 as	food-derived	antigens.	DCs	are	known	to	traffic	to	the	thymus	and	express	self-antigens	60	 to	T	cells,	resulting	in	antigen-specific	clonal	deletion	(Bonasio	et	al.,	2006).	DCs	also	61	 participate	in	peripheral	self-tolerance	for	autoreactive	T	cells	that	evade	negative	62	 selection	by	inhibiting	their	activation	or	causing	apoptosis	of	the	T	cell	(Villadangos	&	63	 Schnorrer,	2007).	Self-recognition	of	nucleic	acids	can	occur	when	there	is	a	problem	64	 clearing	apoptotic	cells.	In	this	situation,	self-nucleic	acids,	along	with	DNA	and	RNA	65	 binding	proteins	are	phagocytosed	by	the	DCs,	bound	by	TLRs	and	recognized	as	foreign,	66	 leading	to	a	break	in	tolerance,	and	ultimately	autoimmune	diseases	(Iwasaki	&	Medzhitov,	67	 2004).	Autoimmune	diseases,	such	as	systemic	lupus	erythematous,	occur	when	there	is	a	68	
			 5	loss	of	tolerance	to	self-antigens.	Systemic	lupus	erythematous	has	been	found	to	occur	69	 concurrently	with	high	levels	of	the	cytokine	IFNα.	IFNα	stimulates	DC	differentiation,	70	 increases	sensitivity	towards	the	target	and	the	cytotoxicity	of	natural	killer	T	cell	and	71	 CD8+	T	cells,	and	upregulates	of	B	cell	activity	and	antigens	that	are	commonly	mistaken	as	72	 foreign.	Normally,	plasmacytoid	DCs	(pDCs)	produce	IFNα	in	response	to	viral	infection,	73	 stimulating	an	immune	response	(Marshak-Rothstein,	2006).		74	 A	cascade	of	signals,	mediated	by	DCs,	brings	cells	to	infected	tissues	and	initiates	75	 the	development	of	immunological	memory,	or	adaptive	immunity,	against	pathogens	76	 (Banchereau	&	Steinman,	1998).	Upon	signaling	through	various	receptors	(described	77	 below),	DCs	become	activated,	leave	the	periphery,	enter	the	afferent	lymph	and	migrate	78	 towards	secondary	lymphoid	tissues.	It	is	in	the	secondary	lymphoid	tissues	that	DCs	79	 become	mature	and	are	characterized	by	high	levels	of	MHC	and	other	T-cell	co-80	 stimulatory	molecules	(Villadangos	&	Schnorrer,	2007).	DCs	are	able	to	traffic	not	only	to	81	 lymphoid	organs	but	to	bone	marrow	as	well.	Here	they	activate	the	resident	memory	T	82	 cells	that	are	present	in	high	concentrations.	Once	the	DCs	have	entered	the	bone	marrow,	83	 they	have	the	capability	to	present	memory	T	cells	with	antigen,	causing	T	cell	84	 proliferation.	Migration	of	DCs	to	the	lymph	nodes	occurs	due	to	changes	in	DC	surface	85	 receptors	(Cavanagh	et	al.,	2005).	Naïve	T	cells	are	stimulated	by	recognition	of	the	specific	86	 antigen	presented	by	DCs,	as	well	as	the	binding	of	costimulatory	molecules	CD80	and	87	 CD86	on	the	DC	surface	to	CD28	on	the	T	cell	surface.	These	signals	activate	CD4+	T	cells	to	88	 secrete	cytokines	that	activate	CD8+	T	cells.	In	the	periphery,	DCs	can	activate	T	cells	by	89	 suppressing	the	interaction	between	T	regulatory	cells	and	the	pathogen-specific	T	cell	via	90	 interleukin-6	(IL-6)	(Iwasaki	&	Medzhitov,	2004).	Interferon	(IFN)	type	1	cytokines	are	91	
			 6	produced	by	activated	DCs	and	include	IFN-α,	IFN-β,	IFN-λ,	and	IFN-ω.	These	promote	92	 memory	T	cell	development,	inhibit	T	cell	apoptosis,	and	induce	DC	maturation	after	93	 antigen	recognition	(Merad	et	al.,	2013).	DCs	also	produce	a	variety	of	cytokines	that	can	94	 activate	cytotoxic	T	lymphocytes	and	T	helper-1	cells.	Both	cytotoxic	T	lymphocytes	as	well	95	 as	T	helper-1	cells	produce	IFN-γ	when	activated,	which	activates	macrophages.	The	96	 cytokine	IL-4,	secreted	by	DCs,	activates	T	helper-2	cells	and	eosinophils,	and	causes	B	cells	97	 to	transform	into	plasma	cells.	DCs	produce	an	important	cytokine	called	IL-1β,	which	98	 activates	both	natural	killer	cells	(innate	immunity),	and	B	and	T	cells	(adaptive	immunity).	99	 Once	adaptive	immunity	has	developed,	the	immune	response	to	a	specific	pathogen	is	100	 much	faster	and	more	potent	leading	to	more	efficient	pathogen	clearance	upon	secondary	101	 encounter	(Banchereau	&	Steinman,	1998).	102	
	103	
Pattern	Recognition	Receptors	104	 The	basis	of	innate	immune	recognition	by	DCs	is	the	binding	of	PAMPs	to	receptors	105	 on	the	DC.	Pattern	recognition	receptors	(PRRs)	are	receptors	that	recognize	components	106	 of	pathogens	known	as	PAMPs.	Immature	DCs	have	a	high	density	of	PRRs	that	bind	PAMPs	107	 as	well	as	inflammatory	signals	from	other	immune	cells.	Receptors	include	Toll-like	108	 receptors	(TLRs),	nucleotide-binding	oligomerization	domain	proteins,	RIG-I-like	109	 receptors,	and	C-type	lectin	receptors.	DCs	express	between	10	and	15	types	of	TLRs	110	 (Iwasaki	&	Medzhitov,	2004).	TLRs	1,	2,	4,	5,	and	6	are	expressed	on	the	cell	surface	and	111	 detect	bacterial	PAMPs.	The	gram-negative	bacterial	compound,	lipopolysaccharide	(LPS),	112	 is	a	potent	stimulator	of	TLR4	(Iwasaki	&	Medzhitov,	2004).	TLR4	recognition	triggers	the	113	 activation	of	IL-1	and	IL-18	cytosolic	receptors,	and	the	signaling	adaptor	molecules	TRIF	114	
			 7	and	TRAM,	as	well	as	the	expression	of	IFN	type	1.	This	pathway	is	dependent	on	the	115	 myeloid	differentiation	factor	88	(MyD88)	signaling	molecules	(Netea	&	Marodi,	2010).	116	 TLRs	3,	7,	8,	and	9	detect	viral	antigens	and	nucleic	acids.	However,	different	subsets	of	DCs	117	 express	different	TLRs	(Iwasaki	&	Medzhitov,	2004).	Activation	through	different	TLRs	can	118	 lead	to	diverse	cytokine	expression,	yet	common	pro-cytokines	are	interferon-α,	TNFα,	IL-119	 1β	and	IL-12.	Activation	of	DCs	is	also	characterized	by	increased	expression	of	120	 costimulatory	molecules	such	as	CD80,	CD86,	and	CD40	proteins	on	the	cell	surface	121	 (Iwasaki	&	Medzhitov,	2004).		122	 TLRs	are	found	in	the	plasma	membrane,	endosomes,	lysosomes,	and	123	 endolysosomes	and	recognize	PAMPs	such	as	lipoproteins,	lipids,	proteins,	and	nucleic	124	 acids.	As	mentioned	above,	there	are	various	types	of	TLRs	and	when	bound	with	ligand,	125	 induce	the	production	of	different	cytokines,	and	thus	different	cellular	responses.	One	126	 such	TLR,	TLR4	for	example,	recognizes	LPS.	When	LPS	is	bound	to	TLR4,	the	release	of	127	 inflammatory	cytokines	is	stimulated	through	early	NF-κB	activation.	NF-κB	is	a	protein	128	 complex	that	controls	the	transcription	of	pro-inflammatory	genes.	The	TLR4-LPS	complex	129	 is	internalized	from	the	plasma	membrane	into	the	endosome	where,	through	other	130	 signaling	molecules,	NF-κB	is	activated	again,	in	what	is	known	as	late-phase	NF-κB	131	 activation	(Kawai	&	Akira,	2010).		132	 	133	
Antigen	Presentation	134	 DCs	patrol	the	peripheral	tissues	searching	for	antigens	from	exogenous	and	135	 endogenous	sources,	which	are	presented	on	cell	surface	molecules	and	are	used	to	136	 activate	other	immune	cells.	Antigen	presentation	is	very	efficient	in	DCs	due	to	high	levels	137	
			 8	of	MHC	class	I	and	II	molecules	on	the	cell	surface	(Villadangos	&	Schnorrer,	2007).	138	 Antigens	are	acquired	by	DCs	through	a	variety	of	pathways	including	phagocytosis,	139	 macropinocytosis,	endocytosis,	or	receptor-mediated	endocytosis	(Banchereau	&	140	 Steinman,	1998;	Villadangos	&	Schnorrer,	2007).	These	processes	allow	very	small	141	 quantities	of	antigen	to	be	efficiently	acquired	on	the	surface	of	the	DC.	Antigens	from	the	142	 cytosol	are	degraded	by	the	proteasome	and	bind	MHC	class	I	molecules.	MHC	class	I	143	 presents	mainly	endogenous	cell	peptides,	while	MHC	class	II	molecules	are	loaded	with	144	 exogenous	antigens	processed	in	endosomal	compartments	by	proteases	called	cathepsins	145	 in	the	endocytic/phagocytic	pathway.	The	MHC-antigen	complex	is	then	transported	to	the	146	 cell	surface	and	is	displayed	for	up	to	several	days	(Banchereau	&	Steinman,	1998).	Many	147	 viruses	inhibit	the	ability	of	the	DC	to	upregulate	molecules	to	the	cell	membrane.	These	148	 infected	DCs	will	die,	but	a	subset	of	DCs,	CD8+	DCs,	will	sample	the	antigens	from	these	149	 apoptotic	cells	and	present	the	viral	peptides	to	stimulate	anti-viral	lymphocyte	responses	150	 (Villadangos	&	Schnorrer,	2007).		151	 	152	
DC	Characterization		153	 Mouse	DCs	can	be	characterized	ex	vivo	by	a	variety	of	hematopoietic	cell	surface	154	 markers,	most	commonly	CD11c,	CD45,	and	CD103.	However,	none	of	these	markers	are	155	 used	exclusively,	as	not	all	DC	populations	express	each	surface	marker.	In	vivo	DC	156	 differentiation	and	proliferation	is	controlled	by	the	cytokine	Flt3L.	Macrophage	colony	157	 stimulating	factor	(M-CSF)	is	another	cytokine	that	determines	differentiation	and	survival	158	 of	DCs.	The	cytokines	IL34	and	TGF-β1	have	been	shown	to	stimulate	differentiation	of	159	 Langerhans	DCs,	a	subset	of	epidermal	DCs.	In	addition,	granulocyte-macrophage	colony-160	
			 9	stimulating	factor	(GM-CSF)	is	the	canonical	cytokine	used	to	differentiate	mouse	DCs	in	161	
vitro	from	hematopoietic	precursors	(Merad	et	al.,	2013).		162	 There	are	three	types	of	migratory	DCs.	Interstitial	DCs	and	Langerhans	cells,	which	163	 migrate	from	the	dermis	and	subcutaneously,	respectively,	and	blood-derived	DCs.	After	164	 maturation,	interstitial	DCs	do	not	live	very	long,	and	are	thought	to	die	in	the	lymph	node.	165	 Blood-derived	DCs	are	also	called	resident	DCs	because	they	are	always	present	in	the	166	 thymus	and	spleen.	These	cells	develop	within	the	thymus	or	spleen	and	do	not	migrate	to	167	 peripheral	tissue.	They	are	characterized	by	their	expression	of	CD4	and	CD8,	which	are	168	 cell	surface	markers	used	to	differentiate	between	subsets	of	resident	DCs.	There	are	low	169	 levels	of	CD4	and	CD8	expression	on	naïve	DCs,	which	is	upregulated	upon	activation.	170	 These	cells	also	exist	in	an	immature	state	and	are	only	activated	upon	infection.	DCs	in	the	171	 spleen	and	lymph	nodes	sample	for	pathogens	in	the	blood,	since	DCs	circulate	in	the	blood	172	 only	in	low	levels	(Villadangos	&	Schnorrer,	2007).		173	 	174	
Metabolic	Regulation	175	 Binding	of	ligands	to	TLR	induces	metabolic	changes	in	DCs.	Early	TLR	activation	by	176	 LPS	reprograms	DCs	to	change	their	metabolism	to	dramatically	upregulate	glycolysis.	177	 When	activated,	DCs	will	activate	several	key	signaling	complexes	and	secrete	a	variety	of	178	 inflammatory	molecules	that	stimulate	an	immune	response.	The	availability	of	glucose	179	 greatly	influences	whether	DCs	will	become	activated	as	well	as	the	ability	to	perform	180	 immune	effector	functions,	such	as	the	production	of	cytokines	and	ability	to	stimulate	T	181	 cell	activation	(Everts	et	al.,	2014).	The	rapid	increase	in	glycolysis	provides	a	source	of	182	 carbon	that	the	cell	uses	to	synthesize	a	large	amount	of	fatty	acid	lipids	that	aid	in	cytokine	183	
			 10	production	and	secretion	through	the	ER-Golgi	network	(Everts	et	al.,	2014).	Inhibition	of	184	 glycolysis	prevents	DC	activation	via	TLR	ligands	(Malinarich	et	al.,	2015).	Due	to	the	185	 increase	in	glucose	consumption,	instead	of	entering	the	tricarboxcylic	acid	cycle,	the	186	 product,	pyruvate,	is	oxidized	to	lactate,	this	is	called	the	Warburg	effect.	This	effect	also	187	 describes	an	increase	in	the	pentose	phosphate	pathway	rate,	generating	nicotinamide	188	 adenine	dinucleotide	phosphate	(NADPH)	which	is	used	in	anabolic	reactions	as	well	as	to	189	 generate	reactive	oxygen	species	(ROS)	(Kelly	&	O'Neill,	2015).	Inhibition	of	glycolysis	via	190	 the	glucose	analog	2-deoxyglucose	(2DG)	after	stimulation	with	LPS	results	in	decreased	191	 levels	of	the	co-stimulatory	molecules	CD86,	CD80,	and	CD40,	as	well	as	the	inflammatory	192	 cytokines	IL-12,	IL-6,	and	TNFα,	impairing	the	ability	of	DCs	to	activate	T	cells	(Everts	et	al.,	193	 2014).		194	 	195	
Dectin-1	196	 Besides	the	TLR	family,	another	category	of	PRRs	is	the	C-type	lectin	receptors,	197	 which	sense	fungal	pathogens	(Brown	et	al.,	2012).	Dendritic-cell-associated	C-type	lectin-198	 1	(Dectin-1)	receptor	recognition	of	fungal	pathogens	is	sufficient	to	activate	DCs,	but	may	199	 also	work	in	conjunction	with	TLR2	and	4	to	amplify	the	response.	Mice	lacking	Dectin-1	200	 have	been	shown	to	be	significantly	more	susceptible	to	infection	from	a	variety	of	fungal	201	 pathogens	(Netea	&	Marodi,	2010).	Dectin-1	is	present	on	DCs,	macrophages,	monocytes,	202	 neutrophils,	and	some	T	cells.	There	are	isoforms	of	Dectin-1	that	are	displayed	in	a	cell-203	 specific	way.	For	example,	Dectin-1	is	more	highly	expressed	by	cells	at	the	sites	of	possible	204	 entry	of	pathogens	such	as	mucosal	surfaces.	Dectin-1	can	also	function	as	a	co-stimulatory	205	
			 11	molecule,	as	it	has	been	shown	to	bind	CD4+	and	CD8+	T	cells	and	increase	their	206	 proliferation	in	vitro	(Netea	&	Marodi,	2010).		207	 Dectin-1	is	one	of	the	most	prominent	fungal	ligand	receptors,	activated	by	β-glucan.	208	 β-glucan	is	a	yeast	cell	wall	component	found	in	more	than	one	million	fungal	species.	It	is	209	 exposed	when	fungal	pathogens	are	subject	to	degradation	of	the	outer	carbohydrate	layer	210	 by	the	host	innate	immune	responses,	initiated	by	Dectin-2	recognition	by	DCs	of	the	211	 outermost	mannose	layer	(Netea	&	Marodi,	2010;	Reid,	Gow,	&	Brown,	2009).	Similar	to	212	 TLR	activation	of	DCs,	activation	through	Dectin-1	has	been	shown	to	induce	adaptive	213	 immunity	by	stimulating	DC	migration	to	T-cell	areas.	It	has	been	shown	that	a	mutation	in	214	 the	human	Dectin-1	receptor	leads	to	an	increased	risk	of	the	fungal	infection	candidiasis,	215	 caused	by	the	fungi	Candida	albicans,	due	to	a	lack	of	cytokine	production	and	release.	216	 Dectin-1	is	necessary	for	the	uptake	and	destruction	of	fungal	pathogens	as	well	as	the	217	 early	inflammatory	response	(Reid	et	al.,	2009).	Furthermore,	Dectin-1	inhibition	has	been	218	 shown	to	completely	inhibit	IL-1β	production	in	response	to	β-glucans,	showing	a	219	 definitive	link	of	IL-1β	in	the	Dectin-1	pathway	(Gringhuis	et	al.,	2012).		220	 Increases	in	the	glycolytic	rate	activate	the	nucleotide	binding	oligomerization	221	 domain	(NOD)-like	receptor	(NLRP3)	inflammasome,	which	is	a	complex	that	cleaves	pro-222	 IL-1β	to	its	active	form.	The	NLRP3	inflammasome	becomes	activated	when	DCs	recognize	223	 certain	PAMPs	(Gold	&	El	Khoury,	2015).	NLRP3	acts	as	a	cytosolic	sensor	for	PAMPs.	It	can	224	 also	be	activated	by	ATP,	reactive	oxygen	species	(ROS)	and	high	K+	efflux	levels	(Gringhuis	225	 et	al.,	2012).	The	complex	consists	of	a	sensor	protein,	NLRP3,	apoptosis-associated	speck-226	 like	protein,	and	pro-caspase-1	(Gold	&	El	Khoury,	2015).	The	activation	of	caspase-1	leads	227	 to	cleavage	of	the	pro-inflammatory	cytokine	pro-	IL-1β	to	its	active	version,	IL-1β	228	
			 12	(Baldwin,	Brough,	&	Freeman,	2015).	IL-1β	then	acts	as	an	activator	of	other	immune	cells.	229	 In	order	to	activate	the	NLRP3	inflammasome,	two	steps	must	occur	(Gold	&	El	Khoury,	230	 2015).	First,	the	translocation	of	NFĸB	must	occur,	which	is	dependent	upon	the	kinase	Syk	231	 in	Dectin-1	mediated	signaling,	to	initiate	transcription	of	NLRP3	and	pro-IL-1β	(Gringhuis	232	 et	al.,	2012).	NFκB	can	be	released	from	an	inhibitory	complex	by	ROS	such	as	O2-	and	H2O2.	233	 ROS	production	increases	with	increased	rates	of	glycolysis	as	it	is	a	byproduct	of	234	 glycolysis	(Forman	&	Torres,	2002).	DCs	are	dependent	upon	Syk	for	Dectin-1	mediated	IL-235	 2	and	IL-10	production	(Brown,	2006).	A	faster	way	of	activating	the	NLRP3	complex	is	to	236	 deubiquitinate	NLRP3,	preventing	it	from	being	targeted	for	degradation.	The	second	step	237	 in	the	activation	of	the	NLRP3	inflammasome	is	the	assembly	of	the	complex:	NLRP3,	238	 apoptosis-associated	speck-like	protein,	and	pro-caspase-1.	Cathepsin	B,	a	lysosomal	239	 proteolytic	enzyme,	degrades	inhibitory	proteins	that	are	bound	to	NLRP3,	allowing	the	240	 complex	to	form.	Once	the	complex	is	formed,	pro-caspase-1	is	cleaved	to	its	active	form	241	 and	the	complex	can	then	cleave	pro-IL-1β	to	its	active	form	(Gold	&	El	Khoury,	2015).	242	 	243	
Clinical	Relevance		244	 The	importance	of	DCs	is	highlighted	by	DC	deficiency	in	humans,	which	is	245	 accompanied	by	B	cell	and	NK	cell	deficiency.	This	deficiency	is	caused	by	a	mutation	in	the	246	 transcription	factor	GATA-binding	factor	2	(Merad	et	al.,	2013).	Patients	with	this	DC	247	 deficiency	have	minimal	proliferation	of	DCs.	A	second	DC	deficiency	arises	from	IRF8	248	 deficiency,	a	transcription	factor	that	commits	the	cell	to	a	specific	lineage	and	maturation	249	 (Merad	et	al.,	2013).	Langerhans	cells	are	present	in	these	patients,	but	most	of	the	other	250	 DC	subsets	are	absent.	Additionally,	a	mutation	in	adenylate	kinase	2,	which	leads	to	a	251	
			 13	deregulation	in	nucleotide	homeostasis,	impairs	the	formation	of	DCs	and	other	immune	252	 cells	(Merad	et	al.,	2013).		253	 Determining	how	DCs	are	activated	has	implications	for	drug	design,	specifically	for	254	 vaccines.	DC	vaccines	are	designed	with	DCs	loaded	with	a	specific	antigen.	These	DCs	are	255	 supposed	to	activate	the	antigen-specific	T	cell	and	lead	to	proliferation	of	the	T	cells	and	256	 activation	of	an	immune	response	(Figdor,	de	Vries,	Lesterhuis,	&	Melief,	2004).	Typically,	257	 vaccines	utilizing	DCs	have	been	used	in	the	targeting	of	tumor	cells.	In	some	studies	258	 vaccines	have	been	therapeutically	effective	in	activating	T-cells	to	target	tumors.	This	259	 represents	an	exciting	alternative	to	traditional	methods	of	targeting	tumors,	such	as	260	 chemotherapy	or	invasive	surgery.	However,	it	is	critical	to	understand	how	DCs	react	to	261	 different	cytokines	and	environments	and	how	they	activate	the	adaptive	immune	system.	262	 (Brunner	et	al.,	2000).	Other	applications	for	therapeutic	uses	of	DCs	are	becoming	more	263	 apparent,	and	are	especially	important	due	a	lack	of	development	of	new	antibiotics	in	264	 recent	years	(Brown	et	al.,	2012).	The	liberal	prescribing	of	antibiotics	as	well	as	misuse	by	265	 patients	enhances	the	rate	at	which	antibiotic	resistance	develops.	Resistance	develops	266	 through	many	mechanisms	depending	on	the	mode	of	action	of	the	drug.	Superbugs,	or	267	 bacteria	that	are	totally	resistant	to	all	current	antibiotics,	or	to	most	antibiotics	have	been	268	 developing.	The	most	concerning	superbugs	are	Mycobacterium	tuberculosis,	Clostridium	269	
difficile,	and	Staphylococcus	aureus	(Davies	&	Davies,	2010).	At	the	same	time,	research	and	270	 development	of	antifungal	drugs	has	lagged	even	farther	behind	the	development	of	new	271	 antibacterial	drugs.	Although	fungal	pathogens	acquire	resistance	at	a	slower	rate	than	do	272	 bacterial	pathogens,	there	are	multiple	examples	of	almost	ubiquitous	pathogenic	fungi	273	 acquiring	resistance,	especially	Candida	species	and	Cryptococcus	neoformans.	Fungi,	as	274	
			 14	well	are	bacteria,	can	transmit	resistance	between	species,	allowing	for	an	increased	rate	of	275	 resistance	development.	The	mortality	rate	for	fungal	infections	that	have	spread	to	the	276	 blood	or	lungs	is	over	50%,	even	when	patients	receive	treatment	with	multiple	antifungal	277	 drugs	(Vanden	Bossche	et	al.,	1998).	The	number	of	fungal	infections	has	swelled	in	recent	278	 years,	with	the	increase	in	the	number	of	AIDS	patients	as	well	as	patients	undergoing	279	 immunosuppressive	therapy	(Brown,	2006).	Most	fungal	infections	are	not	systemic	and	280	 are	limited	to	the	skin	and	nails,	however,	infections	of	the	mucosa,	orally	and	genitally,	are	281	 common	in	childbearing	women,	HIV/AIDS	patients,	babies,	leukemia	patients,	and	282	 transplant	patients.	These	infections	are	caused	mainly	by	several	Candida	species.	283	 Systemic	infections,	although	less	common,	are	much	more	deadly.	In	the	past,	most	284	 systemic	infections	were	limited	to	immunocompromised	patients,	however	particularly	285	 virulent	strains	of	Cryptococcus	gatti	have	emerged	(Brown	et	al.,	2012).	Nosocomial	286	 infections,	particularly	with	Candida	species	are	also	a	huge	concern	because	most	of	them	287	 are	acquired	through	bloodstream	and	gut	contamination	due	to	invasive	hospital	288	 procedures.	Invasive	Aspergillus	infections	appear	in	tuberculosis,	chronic	obstructive	289	 pulmonary	disorder,	and	leukemia	patients	and	are	nearly	100%	fatal	if	diagnosis	is	290	 delayed.	291	
	There	are	often	serious	side	effects	when	using	antifungal	drugs.	This	occurs	for	a	292	 variety	of	reasons	including	problems	with	bioavailability	in	target	tissues,	drug	293	 interactions,	resistance,	and	toxicity.	Since	fungal	cells	are	much	more	similar	to	our	own,	294	 there	are	more	severe	side	effects	as	human	cells	might	be	partially	affected	by	antifungal	295	 treatments.	Antifungal	therapies	are	expensive	because	doses	must	be	monitored	due	to	296	 patient	variation	in	drug	absorption	and	metabolism	as	well	as	the	extended	period	of	time	297	
			 15	that	antifungals	must	be	taken-sometimes	lifelong	treatment.	No	vaccines	currently	exist	298	 against	fungal	pathogens,	and	current	vaccine	technology	would	not	be	sufficient	to	299	 stimulate	a	T	cell	response	in	immunocompromised	patients.	AIDS	patients	especially	are	300	 lacking	CD4+	T	cells,	so	CD8+	T	cells	must	be	activated	directly	(Brown	et	al.,	2012).	301	 Understanding	how	DCs	mediate	the	immune	response	to	different	pathogens	is	critical	to	302	 developing	vaccines	and	treatments	for	a	variety	of	prevalent	and	deadly	medical	issues.		303	 	304	
Hypothesis	305	 Unlike	TLR	activation	dependence	upon	glucose,	the	link	between	the	metabolic	306	 changes	that	occur	in	DCs	as	they	are	activated	through	Dectin-1	mediated	signaling	307	 pathways	has	not	been	heavily	researched.	In	TLR	activation	of	DCs,	a	glycolytic	burst	308	 accompanies	the	production	of	cytokines	and	other	pro-inflammatory	markers.	Inhibition	309	 of	glycolysis	through	hexokinase	inhibitors,	as	well	as	genetic	knockouts	has	been	shown	to	310	 decrease	the	activation	of	DCs	in	response	to	TLR	agonists	(Everts	et	al.,	2014).	This	project	311	 will	focus	on	how	dendritic	cells	respond	to	metabolic	changes	in	their	environment	when	312	 activated	by	fungal	ligands,	as	compared	to	well-known	responses	exhibited	during	313	 activation	by	bacterial	ligands.	To	explore	the	Dectin-1	pathway,	we	will	determine	if	an	314	 increase	in	glucose	metabolism	is	important	in	the	activation	of	DCs	by	fungal	ligands	by	315	 measuring	the	amount	of	inflammasome-dependent	cytokine	production	of	IL-1β.	To	316	 accomplish	this,	DCs	will	be	activated	with	multiple	fungal	ligands	and	the	bacterial	ligand	317	 LPS	as	a	control.	Cells	will	be	activated	in	the	presence	or	absence	of	the	hexokinase	318	 inhibitor,	2DG.	The	regulation	of	activation	will	be	analyzed	through	a	variety	of	detection	319	 methods	including	metabolic	flux	assays,	flow	cytometry,	real	time	PCR,	ELISA	assays,	and	320	
			 16	Western	blot	analysis.	We	hypothesize	that	the	glycolytic	burst	accompanying	activation	321	 through	Dectin-1	pathways	is	necessary	for	DC	activation.		322	 	323	
Materials	and	Methods	324	
Mouse	DC	culture	and	activation		325	 	 	C57BL/6	mice	were	from	The	Jackson	Laboratory	and	were	maintained	under	326	 specific	pathogen-free	conditions	under	protocols	approved	by	Institutional	Animal	Care	327	 and	Use	Committees.	Bone	marrow	cells	were	differentiated	in	the	presence	of	GM-CSF	(20	328	 ng/ml)	in	complete	DC	media	(RPMI	1640	containing	10%	FCS,	100	U/ml	penicillin/	329	 streptomycin,	and	2	mM	L-glutamine)	for	6	days	at	37°C	and	5%	CO2.	On	day	6	of	culture,	330	 DCs	were	washed	in	complete	DC	media	and	were	resuspended	at	1	million	cells	per	mL.	331	 Cells	were	incubated	in	6	well	plates,	1	million	cells/well,	in	a	total	volume	of	2	mL	in	332	 untreated,	LPS,	Zymosan,	and	Zymosan-Depleted	conditions,	in	the	presence	and	absence	333	 of	2DG.	LPS	(Escherichia	coli	sero-	type	0111:B4)	from	InvivoGen	was	used	at	100	ng/ml.	334	 Zymosan	Depleted	(Saccharomyces	cerevisiae)	from	InvivoGen	was	used	at	100	μg/mL.	335	 Zymosan	(Saccharomyces	cerevisiae)	from	InvivoGen	was	used	at	10	μg/mL	(Amiel	et	al.,	336	 2014)	and	2DG	from	Sigma	at	10	mM.		After	four	hours,	cells	were	harvested	via	scraping,	337	 washed	with	sterile	PBS,	and	the	cell	pellet	was	frozen	at	-20	°C	until	RNA	extraction	338	 (Amiel	et	al.,	2014;	Everts	et	al.,	2014).		339	 	340	
Seahorse	Metabolic	Flux	Analysis		341	 	 1.2X105	cells	per	well	were	added	into	a	96-well	Seahorse	plate.	Cells	were	342	 stimulated	with	LPS,	Zymosan,	and	Zymosan-depleted	as	indicated	above	and	real-time	343	
			 17	glycolytic	flux	was	measured.	Where	indicated,	cells	were	pre-treated	with	either	2-DG	or	344	 Syk	inhibitor	PRT	prior	to	TLR/Dectin-1	stimulation.	PRT	was	from	Selleckchem	and	used	345	 at	10	μM.	Extracellular	acidification	rate	(ECAR)	was	measured	every	6	minutes	for	1.5	346	 hours	to	record	changes	in	glycolytic	rate	following	indicated	treatments.		347	 	348	
DC	Activation	349	 	 Cells	were	plated	1x105	cells	per	well	in	5	mM	glucose	solution	or	5	mM	350	 glucose+2DG	for	30	minutes	in	order	to	deplete	intracellular	glucose	and	glycogen	stores	351	 before	stimulation	with	LPS,	zymosan,	zymosan	depleted	and	2DG	in	the	above	352	 concentrations	for	three	hours	in	the	presence	of	a	Golgi	inhibitor.	DC	maturation	was	353	 measured	through	staining	of	TNFα,	IL-12,	and	CD11c.	Fluorescence	was	detected	by	flow	354	 cytometry.		355	 	356	
RNA	Extraction	and	Preparation	357	 	 RNA	was	extracted	from	the	cells	cultured	and	activated	for	4	and	24	hours	as	358	 described	above	using	the	Qiagen	RNeasy	Mini	Kit	and	protocol.	cDNA	was	made	using	the	359	 extracted	RNA.	Samples	were	quantified	using	a	Nanodrop	as	well	as	UVM	Advanced	360	 Genome	Technologies	Core	Facility	where	RNA	integrity	was	determined.	We	used	a	361	 threshold	of	RNA	Integrity	Number	of	6.5	to	determine	which	samples	were	of	high	enough	362	 quality	to	undergo	Real	Time	PCR.		363	 	364	
Real	Time	PCR	365	
			 18		 Real	Time	PCR	was	used	to	determine	the	relative	concentrations	of	IL-1β	366	 transcripts	in	each	sample	that	was	prepared	by	RNA	extraction.	β-actin	acted	as	an	367	 endogenous	control.	Taqman	Fast	Advanced	Master	Mix	was	used	along	with	IL-1β	and	β-368	 actin	primers.	Results	were	then	analyzed	and	plotted	using	GraphPad	Prism.		369	 	370	
Enzyme-linked	immunosorbent	assay	(ELISA)	371	 	 The	R&D	Systems	DuoSet	ELISA	Mouse	IL-1β/IL-1F2	kit	and	protocol	were	used.	372	 Supernatant	was	obtained	from	cells	stimulated	for	four	hours	and	twenty-four	hours,	as	373	 described	above	in	the	Mouse	DC	culture	and	activation	section,	and	was	used	undiluted	374	 and	two	times	diluted,	respectively.	Cells	were	seeded	2x105	cells	per	well	in	a	96	well	375	 plate.	Treatments	were	LPS	(Escherichia	coli	sero-	type	0111:B4)	from	InvivoGen	used	at	376	 100	ng/ml,	Zymosan	Depleted	(Saccharomyces	cerevisiae)	from	InvivoGen	used	at	100	377	 μg/mL	and	Zymosan	(Saccharomyces	cerevisiae)	from	InvivoGen	used	at	10	μg/mL	(Amiel	378	 et	al.,	2014)	2DG	was	used	at	10	mM	as	previously	published	(Everts	et	al.,	2014).	Results	379	 were	analyzed	on	Excel,	and	graphed	using	GraphPad	Prism.			380	 	381	
Western	Blot	382	 	 4x106	cells	per	well	were	seeded	in	a	6-well	plate.	Cells	were	stimulated	with	LPS,	383	 LPS+Nigericin,	Zymosan,	and	Zymosan-depleted,	as	described	above.	Nigericin	was	from	384	 Invivogen	and	was	used	at	1μM.	Where	indicated	cells	were	also	treated	with	2DG.	Cells	385	 were	incubated	for	24	hours	before	lysates	were	collected.	Samples	were	run	on	386	 polyacrylamide	gel	with	the	Precision	Plus	Protein	Standards	Kaleidoscope	ladder	and	387	 transferred	using	Tans-Blot	Turbo	Blotting	System	from	BioRad.	388	
			 19		389	
Results		390	 	 Upon	stimulation	with	TLR	ligands,	DCs	switch	their	metabolism	to	upregulate	391	 glycolysis	(Everts	et	al.,	2014).	To	test	the	hypothesis	that	activation	through	the	C-type	392	 lectin	receptor,	Dectin-1,	also	induces	a	glycolytic	burst	we	performed	a	real-time	ECAR	393	 assay.	We	stimulated	cells	with	LPS,	a	TLR	ligand,	Zymosan,	a	TLR/Dectin-1	ligand,	and	394	 Zymosan-depleted,	a	Dectin-1	specific	ligand.	We	measured	ECAR	over	time	in	the	presence	395	 and	absence	of	a	hexokinase	inhibitor,	2DG,	and	a	Syk	inhibitor,	PRT	(Figure	1	and	2).	We	396	 found	that	activation	through	both	TLR	and	Dectin-1	receptors	is	associated	with	an	397	 immediate	and	sustained	increase	in	glycolysis,	which	was	inhibited	by	2DG	(Figure	1).	398	 These	data	confirm	our	hypothesis	that	a	glycolytic	burst	occurs	when	DCs	recognize	399	 PAMPs	and	is	conserved	for	the	C-type	lectin	receptor,	Dectin-1.	400	 	401	
	Figure	1		Seahorse	Metabolic	Flux	Analysis	of	the	extracellular	acidification	rate	versus	time.	At	“Injection	1”	(first	vertical	green	bar)	cells	were	stimulated	with	either	plain	media	(M)	or	2DG	(10	mM).	At	“Injection	2”	(second	vertical	green	bar)	LPS	(100	ng/mL),	Zymosan	(10	μg/mL),	or	Zymosan-depleted	were	injected	(100	μg/mL).	ECAR	was	measured	to	indicate	real-time	metabolic	flux	in	response	to	the	stimuli.			





			 22	Previous	work	has	shown	that	activation	of	DCs	through	TLRs	leads	to	an	417	 upregulation	of	the	inflammatory	cytokines	IL-12	and	TNFα,	and	inhibition	of	the	glycolytic	418	 burst	via	2DG	inhibits	the	production	of	these	inflammatory	cytokines	(Everts	et	al.,	2014).	419	 We	tested	if	this	phenomenon	was	conserved	when	DCs	are	activated	through	Dectin-1	420	 receptors.	DC	maturation	using	flow	cytometry	was	used	to	identify	levels	of	IL-12	(Figure	421	 3A)	and	TNFα	(Figure	3B)	between	LPS,	zymosan,	and	zymosan	depleted,	and	2DG	treated	422	 cells.	The	blue	histogram	represents	423	 levels	of	expression	in	untreated	424	 cells,	and	the	red	represents	the	425	 percent	increase	in	cytokine	426	 production	when	the	cells	were	427	 activated.	There	is	a	significant	428	 increase	in	both	IL-12	and	TNFα	429	 expression	from	untreated	to	cells	430	 treated	with	LPS,	Zymosan,	and	431	 Zymosan-depleted.	In	the	2DG	432	 treated	cells,	production	of	IL-12	and	433	 TNFα	is	significantly	decreased	434	 across	all	ligands	compared	to	the	435	 non-2DG	treated	cells.	This	436	 information	supports	our	hypothesis	437	 that	signaling	through	Dectin-1	438	
	 	Figure	4	Real	Time	PCR.	Cells	were	stimulated	with	LPS	(100	ng/mL),	Zymosan	(10	μg/mL),	Zymosan-depleted	(100	μg/mL),	and	2DG	(10	μM).	RNA	was	extracted	after	4	hours	of	stimulation,	made	into	cDNA	using	PCR,	analyzed	for	quality,	and	analyzed	via	real	time	PCR.	Data	are	the	mean	±	s.d	of	5	biological	replicates.	A	paired	T	test	was	used	to	determine	there	were	no	significant	differences	in	the	presence	or	absence	of	2DG.	









			 24	analyzed	for	quality	and	used	for	real	time	PCR	analysis	(Figure	4).	LPS	induced	a	30-fold	461	 increase,	Zymosan	about	25-fold	increase,	and	Zymosan-depleted	a	10-fold	increase	in	IL-462	 1β	mRNA	expression.	When	analyzed	by	a	paired	T	test,	there	was	no	significance	between	463	 groups	in	the	presence	or	absence	of	2DG.	This	indicates	the	IL-1β	transcript	levels	are	not	464	 affected	by	glycolysis.		465	 According	to	previous	studies	on	glycolysis	and	TLR	activation,	glycolytic	inhibition	466	 negatively	impacted	inflammatory	cytokine	and	protein	translation	and	secretion	((Everts	467	 et	al.,	2014)	and	Figure	3).	To	assess	whether	this	is	also	true	for	IL-1β	secretion,	ELISA	468	 assays	were	performed	on	supernatants	of	cells	stimulated	for	24	hours	(Figure	5)	with	469	 LPS,	Zymosan,	and	Zymosan-depleted,	in	the	presence	or	absence	of	2DG.	This	assay	470	 detects	both	pro-IL-1β	and	IL-1β	in	the	supernatant	and	compares	the	levels	to	an	IL-1β	471	 standard.	There	was	a	significant	increase	in	IL-1β	secretion	with	the	addition	of	2DG	in	472	 both	the	LPS	and	Zymosan	groups,	however	not	in	the	Zymosan-depleted	group	(Figure	5).	473	 This	was	not	the	direction	expected	since	literature	has	shown	that	mRNA	transcripts	474	 decrease	in	the	presence	of	2DG	(Everts	et	al.,	2014).	These	data	indicate	that	glycolytic	475	 inhibition	does	affect	the	steady	state	levels	IL-1β.		476	 	 Previous	work	has	shown	that	the	production	of	cytokines	including	IL-6,	IL-12,	and	477	 TNFα	is	translationally	controlled	by	glycolysis	((Everts	et	al.,	2014)	and	Figure	3).	We	478	 decided	to	test	if	this	is	true	for	IL-1β	production	using	Western	blot	analysis.	Cells	were	479	 stimulated	with	LPS,	LPS	+	Nigericin	(N),	which	provides	Signal	2	in	inflammasome	480	 activation	since	LPS	alone	only	provides	Signal	1,	Zymosan,	and	Zymosan-depleted,	in	the	481	 presence	or	absence	of	2DG	(Bryant	&	Fitzgerald,	2009;	Gross	et	al.,	2009;	Zhou,	Yazdi,	482	 Menu,	&	Tschopp,	2011).	Figure	6	is	a	representative	blot	of	IL-1β	found	in	cellular	lysates	483	
			 25	after	24	hours	of	activation	of	an	experiment	that	has	been	performed	twice.	A	band	484	 corresponding	to	the	expected	size	of	pro-IL-1β	(32	kD)	was	observed	in	the	LPS,	Zymosan,	485	 and	Zymosan-depleted	lanes	for	non-2DG	treated	cells,	but	not	the	LPS+N	lane.	These	486	 findings	indicate	that	IL-1β	may	have	been	exported	from	the	cell	in	the	LPS+N	group	since	487	 Nigericin	provides	Signal	2	in	inflammasome	activation	and	is	known	to	support	cleavage	488	 and	export	of	IL-1β.	In	the	2DG	treated	cells	there	are	no	bands,	indicating	that	glycolysis	489	 may	play	a	role	in	IL-1β	production,	in	contrast	to	the	ELISA	data.		490	
	491	
Discussion	492	 	 TLR	activation	in	dendritic	cells	induces	a	glycolytic	burst	(Everts	et	al.,	2014).	Up	493	 until	now,	metabolic	reprogramming	by	other	PRRs	has	not	been	well	defined.	Our	works	494	 shows	that	the	stimulation	of	DCs	with	both	TLR	and	Dectin-1	ligands	leads	to	a	dramatic	495	 increase	in	glycolysis	within	4	hours	of	stimulation.	The	glycolytic	burst	is	measured	using	496	 extracellular	acidification	rates.	Glycolysis	is	anaerobic,	meaning	pyruvate	is	the	final	497	
Figure	6	Western	blot.	Cells	were	stimulated	with	LPS	(100	ng/mL),	Zymosan	(10	μg/mL),	and	Zymosan-depleted	(100	μg/mL),	in	the	presence	or	absence	of	2DG	(10	μM).	After	4	hours,	Nigericin	(N)	was	added	where	indicated.	Lysates	were	collected	after	stimulation	for	24	hours.	This	is	a	representative	blot	of	two	experiments.		
Pro-IL-1β		
			 26	electron	acceptor	and	is	converted	into	lactic	acid,	causing	media	to	become	acidic.	The	498	 faster	the	rate	of	glycolysis,	the	faster	the	media	will	become	acidified.	This	rate	of	499	 acidification	is	what	is	measured	to	determine	the	rate	of	glycolysis.	Glycolysis	increases	500	 almost	immediately	after	stimulation	with	both	TLR	and	Dectin-1	specific	ligands	and	is	501	 sustained	for	hours.	This	response	can	be	significantly	dampened	in	TLR,	TLR/Dectin-1	and	502	 Dectin-1	activated	cells	with	the	addition	of	2DG,	which	inhibits	hexokinase,	and	therefore	503	 glycolysis.	The	decrease	in	ECAR	indicates	that	the	2DG	effectively	inhibits	the	glycolytic	504	 burst	from	occurring	in	both	TLR	and	Dectin-1	activated	cells.		505	 	 Splenic	tyrosine	kinase	(Syk)	is	important	in	Dectin-1	signaling,	but	not	TLR	506	 signaling.	Syk	is	utilized	by	the	Dectin-1	ligand	Zymosan-depleted	and	partially	so	by	the	507	 TLR/Dectin-1	ligand	Zymosan.	Syk	activation	is	particularly	important	in	ROS	production,	508	 indicating	that	Syk	is	important	in	innate	immunity	(Underhill,	Rossnagle,	Lowell,	&	509	 Simmons,	2005).	It	has	been	established	that	Dectin-1	activation	is	Syk-dependent	and	can	510	 be	inhibited	using	the	Syk	inhibitor	PRT.	The	LPS	induced	glycolytic	rate	does	not	change	in	511	 the	presence	of	PRT	because	TLRs	do	not	signal	through	Syk	(Underhill	et	al.,	2005)	512	 However,	as	mentioned	above,	Zymosan	activated	cells	do	experience	a	partial	decrease	in	513	 glycolytic	rate	in	the	presence	of	PRT,	but	since	part	of	the	signal	is	through	TLR2,	this	514	 decrease	is	not	nearly	as	pronounced	as	with	Zymosan-depleted	cells.	Zymosan-depleted	515	 cells	when	treated	with	PRT	experience	a	complete	inhibition	of	the	glycolytic	burst.	The	516	 data	illustrate	that	Syk	is	critical	for	the	activation	of	DCs	through	Dectin-1,	and	that	517	 zymosan	depleted	is	specific	for	Dectin-1	with	respect	to	glycolytic	reprogramming	in	DCs.		518	 	 The	activation	of	DCs	in	response	to	pathogen	recognition	can	be	measured	through	519	 a	variety	of	cytokines	including	IL-12,	and	TNFα	(Brunner	et	al.,	2000).	Both	the	TLR	and	520	
			 27	Dectin-1	stimulated	cells	experienced	dramatic	upregulation	of	these	cytokines,	which	was	521	 inhibited	with	the	addition	of	2DG.	These	data	indicate	that	both	the	TLR	and	the	Dectin-1	522	 ligands	are	causing	the	activation	and	maturation	of	the	DCs.	They	also	show	that	inhibition	523	 of	the	glycolytic	burst	with	2DG	inhibits	the	maturation	of	DCs.		524	 Previous	work	has	shown	that	transcript	levels	of	various	inflammatory	cytokines	in	525	 response	to	DC	upregulation	are	not	dependent	upon	the	glycolytic	burst.	These	cytokines,	526	 including	IL-6,	IL-12,	and	TNFα,	have	been	measured	in	the	presence	and	absence	of	2DG	527	 and	were	not	found	to	be	significantly	different	between	the	two	groups	in	LPS	treated	cells	528	 (Everts	et	al.,	2014).	The	results	are	consistent	with	this	work	as	measured	by	real	time	529	 PCR.	mRNA	levels	between	the	2DG	treated	cells	and	non-2DG	cells	did	not	differ	530	 significantly.	IL-1β	transcript	levels	do	not	appear	to	be	regulated	by	the	glycolytic	burst	531	 (Figure	4).		532	 In	contrast	to	the	transcriptional	data,	inflammatory	cytokine	translation	as	533	 measured	by	protein	levels	has	been	shown	to	be	under	glycolytic	control	(Everts	et	al.,	534	 2014).	Work	on	TLR	signaling	shows	that	inhibition	of	glycolysis	with	2DG	effects	535	 production	of	CD40,	CD86,	MHC	class	I	and	II	molecules,	IL-6,	and	IL-12	on	a	translational	536	 level	(Everts	et	al.,	2014).	Since	these	various	inflammatory	cytokines	were	affected	537	 translationally,	this	is	what	we	expected	to	find	for	IL-1β.	We	found	that	secreted	IL-1β	538	 levels	as	detected	by	ELISA	did	change	significantly	when	2DG	was	present	in	the	LPS	and	539	 Zymosan	groups,	however	not	in	the	expected	direction.	Levels	of	IL-1β	increased	in	the	540	 presence	of	2DG.	There	was	no	significant	difference	in	the	Zymosan	depleted	groups	in	the	541	 presence	or	absence	of	2DG.	Because	the	ELISA	kit	measures	both	pro-IL-1β,	which	is	the	542	 un-cleaved	form	of	IL-1β,	as	well	as	cleaved	IL-1β,	we	were	unable	to	distinguish	whether	543	
			 28	the	inflammasome	was	activated	or	not	in	response	to	glycolysis	inhibition.	However,	the	544	 ELISA	data	supports	the	possibility	that	there	is	a	translational	deficit	in	the	presence	of	545	 2DG	for	TLR	receptor	signaling,	but	it	is	unclear	as	to	whether	this	is	also	true	for	Dectin-1	546	 receptor	signaling.		547	 Western	blot	analysis	suggests	that	there	may	be	a	dependence	on	the	glycolytic	548	 burst	for	the	production	of	IL-1β	in	both	the	TLR	and	Dectin-1	signaling.	Since	the	ELISA	549	 assay	measures	extracellular,	or	secreted	IL-1β,	it	is	unclear	whether	a	change	in	IL-1β	550	 levels	are	due	to	a	translational	deficit	or	inflammasome	complex	formation,	so	this	needs	551	 to	be	measured	by	Western	blot	analysis.	The	lysates	in	the	Western	contain	only	552	 intracellular	IL-1β.	Another	difference	is	that	the	Western	is	able	to	detect	the	difference	553	 between	the	pro	versus	cleaved	IL-1β.	The	LPS+N	lane	showed	no	band,	which	suggests	554	 that	at	24	hours	the	IL-1β	was	secreted	from	the	cell.	Supernatant	analysis	will	be	555	 necessary	to	determine	if	this	is	accurate.	There	is	also	a	discrepancy	between	IL-1β	and	556	 other	inflammatory	cytokine	secretion	that	needs	to	be	taken	into	account.	IL-1β	does	not	557	 undergo	the	traditional	ER/Golgi	secretion	pathway	because	it	lacks	a	signal	peptide	558	 (Lopez-Castejon	&	Brough,	2011).	IL-1β	production	is	controlled	by	two	signals.	The	first	559	 signal	induces	the	translation	of	IL-1β	in	the	pro	form.	Signals	include	recognition	of	560	 PAMPs	through	PRRs,	this	is	provided	by	both	TLR	and	Dectin-1	signaling	(Bryant	&	561	 Fitzgerald,	2009;	Gross	et	al.,	2009).	A	second	signal	is	required	for	pro-IL-1β	to	be	cleaved	562	 and	secreted	in	the	active	form.	This	signal	is	typically	another	PAMP,	or	danger	associated	563	 molecular	pattern,	however,	signaling	through	the	Dectin-1	receptor	provides	both	the	first	564	 and	second	signal	(Lopez-Castejon	&	Brough,	2011).	IL-1β	is	cleaved	to	the	active	form	by	565	 the	NLRP3	inflammasome.	The	NLRP3	inflammasome	becomes	active	when	apoptosis-566	
			 29	associated	speck-liked	protein	(ASC)	binds	and	recruits	pro-caspase-1	via	CARD	(Lopez-567	 Castejon	&	Brough,	2011).	At	this	point,	caspase-1	becomes	activated	and	is	able	to	cleave	568	 pro-IL-1β	to	its	active	form,	which	is	secreted	from	the	cell.	Secretion	of	IL-1β	is	not	well	569	 understood,	but	it	is	known	to	occur	through	exocytosis	of	vesicles	that	were	targeted	for	570	 the	lysosome,	through	the	shedding	of	microvesicles,	or	terminal	release	when	cells	die	571	 (Brough	&	Rothwell,	2007;	Lopez-Castejon	&	Brough,	2011).	Western	blot	analysis	shows	572	 no	band	in	the	LPS+N	group,	which	we	interpreted	as	possibly	having	been	excreted	in	the	573	 cleaved	form	since	Nigericin	provides	the	second	signal	for	inflammasome	activation,	574	 however	it	is	unclear	why	Zymosan	and	Zymosan-depleted	are	not	providing	the	same	575	 results	in	this	assay.	576	 	 Future	directions	of	this	work	include	fine-tuning	the	ELISA	to	determine	why	the	577	 Zymosan-depleted	group	did	not	lead	to	as	dramatic	of	an	upregulation	in	IL-1β	production	578	 as	we	have	observed	in	some	of	our	other	unpublished	data.	The	ELISA	also	cannot	579	 distinguish	between	the	pro	and	cleaved	forms	of	IL-1β,	making	Western	blot	analysis	data	580	 the	next	step.	Potential	Western	blot	analysis	work	will	include	the	development	of	a	581	 protocol	that	allows	IL-1β	to	be	detected	in	the	supernatant.	No	accumulation	of	IL-1β	was	582	 observed	in	cell	lysates	treated	with	2DG	at	24	hours,	indicating	that	it	may	have	been	583	 excreted	into	the	supernatant.	However,	there	were	bands	in	the	Zymosan	and	Zymosan-584	 depleted	groups,	which	supposedly	provide	the	second	signal	for	IL-1β	production.	585	 Additional	development	will	move	the	assay	from	qualitative	to	quantitative	with	the	586	 addition	of	a	housekeeping	gene.	An	earlier	time	point	will	also	need	to	be	observed,	587	 around	4	hours	because	that	is	when	the	glycolytic	burst	is	actively	occurring.	According	to	588	 Moon	et	al.,	glucose-dependent	ROS	signaling	is	what	activates	the	inflammasome	to	cleave	589	
			 30	IL-1β.	Further	work	on	ROS	signaling	will	need	to	be	completed.	There	also	may	be	a	590	 difference	in	signaling	between	Hexokinase	1	and	2,	2DG	inhibits	both,	so	we	were	not	able	591	 to	elucidate	any	differences	(Moon	et	al.,	2015).	DCs	are	the	bridge	between	the	innate	and	592	 adaptive	immune	systems;	understanding	how	they	are	activated	and	respond	to	various	593	 conditions	will	allow	an	advance	in	the	therapeutic	uses	of	DCs.		594	 	595	
Conclusion	596	 We	have	shown	that	glycolytic	reprogramming	occurs	in	cells	stimulated	with	both	597	 TLR	and	Dectin-1	ligands.	This	glycolytic	burst	can	be	inhibited	by	the	hexokinase	inhibitor	598	 2DG.	The	glycolytic	burst	is	also	inhibited	by	the	Syk	inhibitor,	PRT,	in	Dectin-1	stimulated	599	 cells	only,	indicating	that	Zymosan-depleted	is	Dectin-1	specific.	Production	of	IL-12	and	600	 TNFα	is	dependent	upon	the	glycolytic	burst,	as	shown	by	the	decreased	levels	of	cytokines	601	 in	the	presence	of	2DG.	When	observing	IL-1β	mRNA	levels,	we	determined	that	mRNA	602	 transcript	levels	do	not	appear	to	be	regulated	by	glycolysis.	It	is	unclear	whether	IL-1β	603	 secretion	is	effected	through	Dectin-1	signaling	by	glycolysis.	ELISA	data	shows	that	……	604	 Our	Western	blot	analysis	results	are	currently	inconclusive	as	to	whether	the	first	or	605	 second	signal	in	inflammasome	activation,	and	thus	pro-IL-1β	cleavage,	is	dependent	on	606	 glycolysis.	These	studies	have	begun	to	develop	a	better	understanding	of	the	mechanisms	607	 in	which	DCs	are	activated	in	response	to	Dectin-1	signals.	Further	studies	addressing	the	608	 remaining	questions	outlined	above	may	have	important	implications	regarding	our	609	 understanding	of	anti-fungal	innate	immune	recognition	and	potentially	contribute	to	610	 improved	anti-fungal	vaccine	design	(Nouri-Shirazi,	Banchereau,	Fay,	&	Palucka,	2000).			611	 	612	
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